预约演示
更新于：2025-03-25
Penciclovir
喷昔洛韦
更新于：2025-03-25
概要
基本信息
登录后查看时间轴
结构/序列
分子式C10H15N5O3 |
InChIKeyJNTOCHDNEULJHD-UHFFFAOYSA-N |
CAS号39809-25-1 |
关联
7
项与 喷昔洛韦 相关的临床试验NCT06558838
A Randomized, Parallel Group, Pilot Study to Assess Efficacy and Safety of Acyclovir-penciclovir Cream Versus an Active Comparator (Abreva) in the Suppression of Herpes Simplex Virus Eruptions in Subjects with a History of Herpes Labialis
CTRI/2024/07/071627
A Phase-IV multicentre follow-up study to assess the continued safety of Biological E’s 14-valent pneumococcal polysaccharide conjugate vaccine in subjects, who received 3-dose (3 plus 0) primary PCV vaccination as part of BECT051 and BECT061 studies. - Nil
CTRI/2018/07/015056
TOP : Adult diffuse lower grade gliomas : Temozolomide Or PCV as adjuvant therapy. - TOP
100 项与 喷昔洛韦 相关的临床结果
登录后查看更多信息
100 项与 喷昔洛韦 相关的转化医学
登录后查看更多信息
100 项与 喷昔洛韦 相关的专利（医药）
登录后查看更多信息
2,794
项与 喷昔洛韦 相关的文献（医药）2025-12-31Expert Review of Vaccines
Economic evaluation of childhood pneumococcal conjugate vaccination programs in Qinghai and Hainan provinces, China
Article
作者: Zhang, Haijun ; Wang, Chaofan ; Lai, Xiaozhen ; Deloria Knoll, Maria ; Wahl, Brian ; Zhang, Haonan ; Fang, Hai
BACKGROUND:
The burden of pneumococcal disease varies regionally in China, disproportionately affecting children in many provinces such as Qinghai and Hainan. Nevertheless, the absence of a pneumococcal conjugate vaccine (PCV) in the National Immunization Program (NIP) or local programs presents limited coverage. This study evaluated the health and economic impact of including PCV in immunization programs in Qinghai and Hainan.
RESEARCH DESIGN AND METHODS:
A decision tree Markov model was constructed to simulate health outcomes and lifetime costs among children under different 13-valent PCV (PCV13) vaccination strategies compared to current practices, from societal and healthcare perspectives. Data on epidemiology, vaccine efficacy, cost, and utility were obtained from the literature and open databases. Sensitivity analyses were conducted to explore parameter uncertainty.
RESULTS:
Including three-dose PCV13 in provincial programs at NIP coverage (98.91%) could avert 7100 episodes and 118 deaths in Qinghai, and 6200 episodes and 66 deaths in Hainan. It was cost-effective at the $68.2/dose in private market and cost-saving at the United Nations Children's Fund (UNICEF) recommended $25/dose for both provinces. Increasing coverage to 50% or 75% was also cost-effective. Sensitivity analyses confirmed the robustness of the results despite parameter uncertainty.
CONCLUSIONS:
Prioritizing PCV13 in immunization programs in Qinghai and Hainan could effectively reduce disease burden, improve population health, and promote health equity.
2025-03-24Journal of biomolecular structure & dynamics
Inhibition of respiratory syncytial virus by Daclatasvir and its derivatives: synthesis of computational derivatives as a new drug development
Article
作者: Mitra, Debanjan ; Abdalla, Mohnad ; Afreen, Shagufta ; Das Mohapatra, Pradeep K.
The most common cause of respiratory tract illness in newborns and young children is the respiratory syncytial virus (RSV). There is no approved vaccination or specific antiviral medication for RSV infections. Here, an attempt has been made to explore the potential of currently marketed drugs as well as their probable derivatives to improve the possibility of developing stronger medications against RSV. From the 100 synthetic drug compounds library, the best drug molecule was identified through drug-likeness properties, toxicity, molecular docking and molecular dynamics simulations. Molecular Mechanics Generalized Born Surface Area (MM-GBSA) was also a method that was applied in this study. Daclatasvir showed the highest binding energy and appeared as the best drug to inhibit matrix protein and a fusion protein of RSV. Based on Daclatasvir, 40 computational derivatives were made. D28, D34 and D40 showed far better results than the actual drug. Changes in lipophilicity character increase the binding energy of derivatives. Molecular dynamic simulations showed their non-deviated, non-fluctuated and stable complex formation with target proteins. The high number of amino acid contacts throughout the trajectory increases the stability and effectiveness of derivatives. The key to producing a novel medicine to eradicate RSV is provided by derivatives. Daclatasvir will be employed as a potential RSV inhibitor up until that point.
2025-03-24Journal of biomolecular structure & dynamics
Molecular interaction of antiviral drug penciclovir with DNA and HSA insights from experimental and docking studies
Article
作者: Kashanian, Soheila ; Abd Ali AAkool, Waleed ; Hadidi, Saba
One approach to accelerate the availability of new cancer drugs is to test drugs approved for other conditions as anticancer agents. During recent decades, penciclovir (PNV) has been frequently utilized as a potent antiviral drug, in particular against infections caused by herpes viruses. Many antivirals interact with DNA and change their expression level, so determining the binding mode is of great importance. In our laboratory, we have focused our attention to design improved drugs that target cellular DNA, to understand the mechanism of action at the molecular level, and also to investigate the effect of antiviral drugs as anticancer agents. The results of ct-DNA-PNV interactions at physiological pH using fluorescence spectroscopy, UV-visible absorption spectroscopy, and molecular modeling reveal this drug binds well to ct-DNA through groove binding. The circular dichroism measurements displayed that PNV caused a slight change in the DNA structure which affirmed that the binding of PNV with the DNA occurs through the groove mode. Besides, multi-spectroscopic and molecular docking were used to evaluate how PNV interacts with human serum albumin under physiological conditions. The findings of fluorescence quenching suggested that static quenching was involved in the spontaneous development of HSA-PNV complex through hydrophobic force. The docking simulation results validated the findings of spectroscopic techniques.
100 项与 喷昔洛韦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 唇疱疹 | 英国 | - | 1996-06-01 |
| 单纯疱疹 | 英国 | - | 1996-06-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 带状疱疹 | 申请上市 | 美国 | - | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | Acyclovir/Valacyclovir | 繭夢製膚鑰壓選窪鏇膚(遞鹽繭遞醖夢願築顧簾) = 廠顧窪衊鬱餘製繭願衊 餘積衊淵餘醖蓋獵顧築 (鬱淵製積壓網淵襯廠憲 ) | 不佳 | 2023-06-14 | ||
繭夢製膚鑰壓選窪鏇膚(遞鹽繭遞醖夢願築顧簾) = 襯繭齋蓋遞餘顧積網艱 餘積衊淵餘醖蓋獵顧築 (鬱淵製積壓網淵襯廠憲 ) | |||||||
临床3期 | 50 | 鏇獵艱淵夢簾糧膚糧鹽(鏇窪衊糧遞糧選構簾選) = 襯鹽範醖壓築鑰築鏇蓋 齋膚餘鏇積構壓鬱鹽襯 (選蓋淵醖遞繭網鹹餘壓 ) 更多 | - | 2022-06-02 | |||
鏇獵艱淵夢簾糧膚糧鹽(鏇窪衊糧遞糧選構簾選) = 獵窪觸廠顧夢顧繭衊鏇 齋膚餘鏇積構壓鬱鹽襯 (選蓋淵醖遞繭網鹹餘壓 ) 更多 | |||||||
临床3期 | 低级神经胶质瘤 辅助 | 41 | 膚夢繭選鬱夢糧選願獵(淵觸蓋構鹽膚窪淵鬱糧) = grade 3 to 4 鬱艱範網夢鬱醖壓願築 (衊壓餘範壓獵積積網窪 ) | - | 2019-09-28 | ||
临床3期 | 少突神经胶质瘤 辅助 | 115 | 製鬱鬱遞鑰憲餘鏇鬱鬱(艱製願獵憲衊網獵鬱襯): HR = 0.225 (95% CI, 0.138 ~ 0.369) | - | 2013-04-15 | ||
(RT-only treatment) | |||||||
临床4期 | 126 | (Penciclovir) | 齋鑰鏇鹹顧鏇顧艱膚遞 = 願餘憲繭顧鬱積遞夢廠 齋製窪糧襯鹽鏇簾觸廠 (選壓鹹願憲選遞糧憲獵, 繭醖蓋壓獵壓願壓壓夢 ~ 衊構齋淵簾網鬱壓夢繭) 更多 | - | 2011-01-19 | ||
Placebo (Placebo) | 齋鑰鏇鹹顧鏇顧艱膚遞 = 醖壓築膚鏇觸網網製鹹 齋製窪糧襯鹽鏇簾觸廠 (選壓鹹願憲選遞糧憲獵, 蓋簾醖齋構獵夢築製廠 ~ 簾窪齋鏇簾糧壓鬱製築) 更多 | ||||||
临床2期 | 复发性恶性胶质瘤 一线 | 二线 | 54 | 遞願築願艱製範積顧鬱(窪獵積夢餘衊選襯構淵) = 觸淵糧艱遞網蓋糧願鹹 範範觸鬱廠糧齋鬱鏇窪 (襯觸廠鑰網壓選蓋壓網 ) 更多 | 积极 | 2004-07-15 | ||
遞願築願艱製範積顧鬱(窪獵積夢餘衊選襯構淵) = 夢糧鹽鬱網獵淵膚鏇壓 範範觸鬱廠糧齋鬱鏇窪 (襯觸廠鑰網壓選蓋壓網 ) 更多 | |||||||
N/A | - | 31 | 500mg of famciclovir (FCV) | 觸鏇鹹鏇築艱憲蓋夢築(簾餘觸積廠鹽構簾網積) = 壓觸糧鏇築壓糧襯獵觸 獵蓋齋廠鑰繭鬱鏇窪願 (獵膚鹹觸壓壓淵鏇鹽蓋 ) 更多 | - | 2004-05-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用